Literature DB >> 8469818

Clinical and radiologic features, lung function and therapeutic results in pulmonary histiocytosis X.

N Schönfeld1, W Frank, S Wenig, P Uhrmeister, E Allica, H Preussler, A Grassot, R Loddenkemper.   

Abstract

Clinical appearance, radiologic findings, lung function and results of corticosteroid therapy were analyzed in 42 adult cases of biopsy-proven pulmonary histiocytosis X. Symptoms were present in only 64%. Using the ILO classification 1980, the evaluation of chest radiographs revealed all categories of profusion, size and shape of nodules. The characteristic 'ring figures', i.e. thin-walled cysts, in the parenchyma were detected in 78% of conventional tomographies (n = 27) and in all patients examined by CT (n = 5). In patients with early disease, lung function tests (n = 26) including body plethysmography, pulmonary diffusing capacity and ergospirometry revealed that parameters of gas exchange are most sensitive (TL,CO 84%, KCO 72%). Bronchial reactivity to carbachol was significantly higher than in controls (n = 12). Lung perfusion scintigram showed an abnormal, but uncharacteristic pattern in 81% (n = 26). During corticosteroid therapy, no progression was observed (n = 36). 85% of patients with radiographic evidence of progressive disease improved after administration of corticosteroids (n = 14).

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8469818     DOI: 10.1159/000196171

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  20 in total

Review 1.  Adult pulmonary Langerhans' cell histiocytosis.

Authors:  A Tazi; P Soler; A J Hance
Journal:  Thorax       Date:  2000-05       Impact factor: 9.139

Review 2.  Rare lung diseases III: pulmonary Langerhans' cell histiocytosis.

Authors:  Stephen C Juvet; David Hwang; Gregory P Downey
Journal:  Can Respir J       Date:  2010 May-Jun       Impact factor: 2.409

3.  Pulmonary Langerhans Histiocytosis: an uncommon cause of interstitial pneumonia in a patient with Sjögren syndrome.

Authors:  Andrés González García; José Luis Callejas Rubio; Raquel Ríos Fernández; Norberto Ortego Centeno
Journal:  Clin Rheumatol       Date:  2015-04-19       Impact factor: 2.980

Review 4.  Smoking-related interstitial lung disease.

Authors:  Lars Hagmeyer; Winfried Randerath
Journal:  Dtsch Arztebl Int       Date:  2015-01-23       Impact factor: 5.594

5.  Alveolar macrophages from bronchoalveolar lavage of patients with pulmonary histiocytosis X: determination of phenotypic and functional changes.

Authors:  M Uebelhoer; B Bewig; K Sternberg; K Rabe; D Nowak; H Magnussen; J Barth
Journal:  Lung       Date:  1995       Impact factor: 2.584

6.  Diagnostic relevance of Langerin detection in cells from bronchoalveolar lavage of patients with pulmonary Langerhans cell histiocytosis, sarcoidosis and idiopathic pulmonary fibrosis.

Authors:  Karel Smetana; Otakar Mericka; Sem Saeland; Jirí Homolka; Jirí Brabec; Hans-Joachim Gabius
Journal:  Virchows Arch       Date:  2004-01-13       Impact factor: 4.064

Review 7.  Challenges in pulmonary fibrosis. 3: Cystic lung disease.

Authors:  Gregory P Cosgrove; Stephen K Frankel; Kevin K Brown
Journal:  Thorax       Date:  2007-09       Impact factor: 9.139

Review 8.  Smoking-related interstitial lung diseases: radiologic-pathologic correlation.

Authors:  Alberto Hidalgo; Tomás Franquet; Ana Giménez; Ramón Bordes; Rosa Pineda; Marta Madrid
Journal:  Eur Radiol       Date:  2006-07-25       Impact factor: 7.034

Review 9.  Langerhans cell histiocytosis.

Authors:  Joan Manel Gasent Blesa; Vicente Alberola Candel; Carlos Solano Vercet; Juan Laforga Canales; Christof Semler; Maria Rosa Pérez Antolí; Carlos Rodríguez-Galindo
Journal:  Clin Transl Oncol       Date:  2008-11       Impact factor: 3.340

10.  Morphometrical analysis of transbronchial cryobiopsies.

Authors:  Sergej Griff; Wim Ammenwerth; Nicolas Schönfeld; Torsten T Bauer; Thomas Mairinger; Torsten-Gerriet Blum; Jens Kollmeier; Wolfram Grüning
Journal:  Diagn Pathol       Date:  2011-06-16       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.